A precipitating factor in the development of atherosclerotic lesions is the inappropriate migration and proliferation of vascular smooth muscle cells (SMC) within the intima of the vessel wall. Focusing on the role of extracellular matrix proteins in SMC migration, we have demonstrated that thrombospondin (TSP) itself is a potent modulator of SMC motility and acts to potentiate platelet-derived growth factor (PDGF)-mediated SMC migration as well. Migration of SMC to TSP was dose dependent. Interestingly, maximal SMC migration to TSP exceeded that to either PDGF or basic fibroblast growth factor (bFGF). The distal COOH terminus of TSP was shown to mediate SMC migration a5 demonstrated by complete inhibition of the response by monoclonal antibody (mAb) C6.7. Nevertheless, proteolytic fragments of TSP were not as potent as intact TSP in mediating SMC migration. Only by combining the heparin-binding domain (HBU) with the 140 kD C O O H terminal fragment was SMC migration restored to levels seen with intact TSP. Based on antibody inhibition studies, an a,-containing integrin receptor, but not LY$, or a,P+, appeared to be involved in SMC migration to TSP. The coincidental expression of PDGF and TSP at sites of vascular injury and inflammation led us to evaluate the effect of suboptimal levels of TSP on SMC responsiveness to PDCF. SMC migration in response to PDGF was enhanced nearly 60% in the presence of suboptimal concentrations of TSP. This effect was specific for PDGF and dependent on the concentration of TSP with maximal potentiation obtaincd between 50-1 00 n M TSP, concentrations tenfold lower than those necessary for SMC migration to TSP itself. mAb C6.7 complctely inhibited enhancement but, as with SMC migration to TSP alone, TSP proteolytic fragments did not po effectiveness of the intact molecule. Additional experiments assessing SM tion to PDGF demonstrated that PDGF stimulated SMC motility indirectly by inducing TSP synthesis. These studies suggested that TSP functions as an autocrine motility factor to modulate SMC migration, which in conjunction with PDGF could serve to aaaravate and accelerate development of atherosclerotic lesions at "I, sites of vascular injury or inflammation. (Ross, 1986) . These f u n c t i o n a l changes correlate w i t h t h e m o d u l a t i o n o f t h e SMC phenotype from a quiescent, contractile state t o a synthetic, p r o l i f e r a t i v e state (Chamley-Campbell e t al., 1981). Therefore, t h e signals that s t i m u l a t e SMC m i g r a t i o n and proliferat i o n h a v e been intensively studied in order t o i d e n t i f y relevant pathways and possible nodes o f intervention.
either PDGF or basic fibroblast growth factor (bFGF). The distal COOH terminus of TSP was shown to mediate SMC migration a5 demonstrated by complete inhibition of the response by monoclonal antibody (mAb) C6.7. Nevertheless, proteolytic fragments of TSP were not as potent as intact TSP in mediating SMC migration. Only by combining the heparin-binding domain (HBU) with the 140 kD C O O H terminal fragment was SMC migration restored to levels seen with intact TSP. Based on antibody inhibition studies, an a,-containing integrin receptor, but not LY$, or a,P+, appeared to be involved in SMC migration to TSP. The coincidental expression of PDGF and TSP at sites of vascular injury and inflammation led us to evaluate the effect of suboptimal levels of TSP on SMC responsiveness to PDCF. SMC migration in response to PDGF was enhanced nearly 60% in the presence of suboptimal concentrations of TSP. This effect was specific for PDGF and dependent on the concentration of TSP with maximal potentiation obtaincd between 50-1 00 n M TSP, concentrations tenfold lower than those necessary for SMC migration to TSP itself. mAb C6.7 complctely inhibited enhancement but, as with SMC migration to TSP alone, TSP proteolytic fragments did not po effectiveness of the intact molecule. Additional experiments assessing SM tion to PDGF demonstrated that PDGF stimulated SMC motility indirectly by inducing TSP synthesis. These studies suggested that TSP functions as an autocrine motility factor to modulate SMC migration, which in conjunction with PDGF could serve to aaaravate and accelerate development of atherosclerotic lesions at "I, sites of vascular injury or inflammation.
M i g r a t i o n o f smooth muscle cells (SMC) i n t o t h e vascular intima and t h e i r inappropriate p r o l i f e r a t i o n a r e t h o u g h t t o contribute t o t h e pathology o f atherosclero-
sis (Ross, 1986) . These f u n c t i o n a l changes correlate w i t h t h e m o d u l a t i o n o f t h e SMC phenotype from a quiescent, contractile state t o a synthetic, p r o l i f e r a t i v e state (Chamley-Campbell e t al., 1981) . Therefore, t h e signals that s t i m u l a t e SMC m i g r a t i o n and proliferat i o n h a v e been intensively studied in order t o i d e n t i f y relevant pathways and possible nodes o f intervention.
O n e o f t h e most p o t e n t modulators of SMC m i g r a t i o n and proliferation i s platelet-derived g r o w t h factor (PDGF) (Ross e t al., 1986 ). PDGF i s secreted by activated platelets and macrophages, a m o n g several o t h e r cell types, a t sites of i n f l a m m a t i o n and vascular dam- (' 1993 WILEY-LISS, 1NC 0 1993 Wilcy-Liss, Inc. age. P r o l i f e r a t i o n o f quiescent SMC i s stimulated w i t h i n 24 h o u r s after exposure t o PDGF (Majack e t al., 1990 ). S i m i l a r l y , SMC m i g r a t i o n t o PDGF h a s been demonstrated in v i t r o and, in vivo, PDGF i s believed t o mediate S M C m i g r a t i o n i n t o t h e n e o i n t i m a (Grotendorst e t al., 1982; Clowes and Clowes, 1986) . Overall, these profound effects o n SMC physiology implicate PDGF as a m a j o r factor in t h e propagation o f atherosclerotic lesions.
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Less well studied is the involvement of extracellular matrix (ECM) molecules in SMC behavior. While SMC adhere to ECM components such as fibronectin, collagen, thrombospondin (TSP), and laminin, less is known about the role of ECM in SMC proliferation and migration (Hedin et al., 1988; Lawler et al., 1988) . Recent reports have demonstrated migration of SMC to fibrinogen and vitronectin, two ECM molecules that are abundant in plasma (Naito et al., 1989 (Naito et al., , 1991 . In addition, immunohistochemical analysis has localized high concentrations of fibronectin, collagen, and TSP at sites of atherosclerotic lesions and vascular injury (Raugi et al., 1990; Shekhonin et al., 1987) suggesting that, in vivo, these ECM components are localized in regions of active SMC proliferation and migration.
TSP is unique among ECM proteins in that its concentration in the plasma is fairly low. However, TSP expression increases rapidly and transiently following tissue damage and platelet activation (Mosher, 1990; Lawler, 1986) . Besides platelets, TSP is also secreted by SMC, monocytes, endothelial cells, and fibroblasts. Within 30 minutes of PDGF stimulation TSP mRNA levels in SMC rise dramatically followed by an increase in protein levels within 2 hours (Majack et al., 1985 (Majack et al., , 1987 . The kinetics of TSP mRNA induction and its independence of protein synthesis suggested that TSP is a member of the immediate-early response gene family whose members include fos and myc. The ability of TSP to modulate SMC proliferation, essentially acting as an autocrine growth factor for SMC, was demonstrated in two respects. First, TSP potentiates epidermal growth factor (EGFbdependent mitogenesis (Majack et al., 1986) . Second, TSP was shown to be essential for the proliferative response of SMC to PDGF (Majack et al., 1988 ). These studies demonstrate that TSP is an important modulator of SMC function, and through its restricted pattern of expression in damaged tissue, may play a role in the progression of atherosclerotic lesions.
We have investigated the effect of TSP on SMC motility and have found TSP to be a potent stimulator of SMC migration. Additionally, we found that PDGF and TSP acted synergistically in stimulating migration. These data highlight not only the complex interactions between cells and extracellular signals involved in SMC physiology, but also suggest that the role of ECM proteins may be more integrative than previously realized.
MATERIALS AND METHODS
Materials TSP and TSP fragments were isolated and purified from activated platelets as previously described (Dixit et al., 1984; Yabkowitz and Dixit, 1991) . Platelet TSP is thought to be a TSPl homotrimer (LaBell et al., 1992) . The 70 kD core fragment of TSP was produced by chymotrypsin cleavage of the 140 kD fragment (1:lOO wtl wt) in the presence of 5 mM ethylenediaminetetraacetic acid (EDTA) for 2 hours at 37°C followed by fractionation over a heparin-Sepharose column. The 70 kD fragment was recovered in the flowthrough fractions. Intact TSP was also chymotrypsinized (1:100, wtl wt) for 40 minutes at 37°C and used without further fractionation (Mansfield et al., 1990) . Homogeneity of TSP and TSP fragments was judged by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis to be >95c?. Human PDGF-BB and bFGF were generous gifts from Amgen (Thousand Oaks, CA) and Synergen (Boulder, CO), respectively. TSP-specific monoclonal antibodies (mAbs) have been previously described and characterized (Dixit et al., 1986) . The synthetic peptides GRGDS and GRGES were purchased from Calbiochem (La Jolla, CAI and Penninsula Labs (Belmont, CA), respectively, and were tested a t a concentration of 1 mM. Heparin was purchased from Sigma (St. Louis, MO). Mouse IgG was purchased from Cappel (Malvern, PA) and used at a concentration of 20 pg/ml. Antibodies against cell surface receptors were obtained as follows: mAbs LM142 and LM609 (both used at a dilution of 1:5) were gifts of Dr. David Cheresh (Scripps Clinic, La Jolla, CA); mAb AIIB2 specific for the PI integrin subunit (used at a 1:5 dilution) was a gift of Dr. Caroline Damsky (University of California, San Francisco, CA); mAbs SZ21 specific for the P3 integrin subunit and FA6.152 specific for GPIV (both used at 20 pgiml) were purchased from AMAC (Westbrook, ME); mAb 30 specific for GPIV (used a t 5 pgiml) was a gift of Dr. Graham Jamieson (American Red Cross, Rockville, MD); mAb OKM5 also specific for GPIV (used a t 5 pg/ml) was purchased from Ortho Diagnostics (Raritan, NJ).
Cells
Bovine pulmonary artery SMC were isolated and characterized as described (Ryan and Maxwell, 1992) and used between passages 2 and 10. Cells were grown in Dulbecco's modified eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), nonessential amino acids, 1 mM sodium pyruvate, 100 Uiml penicillin, 100 pgiml streptomycin, and 250 pgiml gentamicin. Confluent SMC were subcultured at 1:3 or 1:4 as needed. SMC were harvested a t 80% confluency by incubation in phosphate-buffered saline (PBS) containing 1 mM EDTA for 3 minutes followed by pipetting cells off the plates. Pooled cells were washed three times in DMEM and allowed to recover for 30 minutes at room temperature before treatment.
Chemotaxis assays Assays were carried out in 48-well chambers (Neuroprobe, Cabin John, MD) using 8 km polycarbonate filters (Nuclepore, Pleasanton, CA) essentially as described (Mansfield et al., 1990; Yabkowitz et al., 1993) . Filters were soaked overnight in 100 p.g/ml gelatin in 0.1% acetic acid a t 37°C to allow the initial attachment of cells (Taraboletti et al., 1987) . TSP, TSP fragments, or growth factors were diluted in DMEM plus 0.1% bovine serum albumin (BSA) and added to the lower wells of the chamber. SMC (3 x 104/well) in the same buffer were added to the upper well of the chamber and the assembled chamber incubated for 6 hours a t 37°C. Filters were fixed and stained with hematoxylin. Three filters were used for each treatment and five fields were scored from each filter under high power magnification (~4 0 0 ) .
Data were expressed as mean number SMC migrating per field 2 S.E.M. Buffer alone in the lower well served as a negative control (0.5 5 0.3 SMC/ field). Where appropriate, statistical analysis for sig-nificance was performed using a one-tailed paired Student's t-test. For inhibition experiments, TSP was preincubated with anti-TSP mAbs for 30 minutes at 37"C, or SMC were preincubated with mAbs against cell surface receptors or synthetic peptides for 30 minutes at room temperature before being added to the lower or upper wells of the chamber, respectively. In experiments where chemoattractants were combined, no preincubation was necessary; the individual components were added directly to the lower wells. For cycloheximide and mAb C6.7 experiments, SMC were preincubated for 16 hours or 30 minutes, respectively, before addition to the upper wells of chemotaxis chambers.
Cycloheximide (10 pglml) or mAb C6.7 was also present throughout the assay period. Treated SMC were evaluated for chemotaxis to either 10 nglml PDGF or 1 pM TSP as described above. All experiments were repeated two to three times.
RESULTS

SMC chemotaxis to TSP
Pulmonary artery SMC demonstrated dose-dependent migration to soluble TSP with a linear increase between 30 and 200 nM TSP and a maximal response seen a t approximately 1 FM (Fig. la) . Directionality of migration (chemotaxis) was established by comparing the response of SMC to TSP placed in either the upper or lower wells; whereas SMC migration to TSP placed in the lower wells was significant, no migration above background was evident when TSP was present in the upper wells (data not shown). We compared the response of SMC to TSP to the responses of SMC to two other well characterized chemoattractants, PDGF-BB and bFGF (Grotendorst et al., 1982; Sat0 et al., 1991) . At their maximal effective concentrations, TSP, on average, elicited a 40% higher response than either PDGF or bFGF (Fig. lb) .
To rule out the possibility that transforming growth factor beta (TGF-p) contamination of our TSP preparations was responsible for the migratory effects observed with SMC (Murphy-Ullrich et al., 1992), we used both a neutralizing anti-TGF-p antibody and purified recombinant TGF-p. In one set of assays, TSP was preincubated with varying concentrations of anti-TGF-@ antibody (up to 100 pg/ml) before addition to the lower wells of chemotaxis chambers. No effect on SMC chemotaxis to TSP was observed over the range of antibody concentrations tested (data not shown). Additionally, spiking our TSP preparations with 0.01-100 ng/ml recombinant TGF-p did not alter SMC chemotaxis to TSP (data not shown). These results indicated that TSPmediated SMC chemotaxis was not a result of TGF-P contamination, but represented a TSP-specific response.
To further demonstrate specificity and determine which domain of the TSP molecule mediated SMC migration, anti-TSP mAbs were screened for inhibition of migration. mAb C6.7, specific for the distal COOH terminus, inhibited SMC migration to TSP (Fig. 2) . None of the other mAbs tested, including mAb A2. not inhibit SMC migration (data not shown). Mouse IgG had no effect (data not shown). Inhibition of migration by mAb C6.7 was dose dependent with partial inhibition evident at 50 kglml antibody and virtually complete inhibition a t 200 pglml (Table 1) .
To further define the TSP domain(s) involved in mediating SMC chemotaxis, assays were also conducted with TSP proteolytic fragments. Surprisingly, no proteolytic fragment retained the potency of intact TSP in mediating SMC migration (Fig. 3) . The 140 kD fragment (140K), containing the mAb C6.7 epitope, partially supported SMC chemotaxis with a maximal response approximately 50% of that seen with intact TSP. SMC migration to 140K was dose dependent, similar to that observed with intact TSP, with a maximal effect observed at 1 FM (data not shown). Both the HBD and the 70 kD core region, derived from the 140 kD fragment, supported a minimal level of SMC migration, a t most 10% of the response to intact TSP. In contrast, the combination of the HBD and 140K was almost as potent as intact TSP (Fig. 3) . The chemotactic response was significantly greater (P < 0.05) than the calculated additive effect of the HBD and 140K individually. Although the HBD itself was relatively ineffective in supporting SMC migration, it appeared to enhance SMC migration to 140K. This enhanced response was consistently observed among several different batches of both the HBD and 140K.
SMC chemotaxis to 140K and the combination of 140K and the HBD was further evaluated in the presence of anti-TSP mAbs ( Table 2) . mAb C6.7 inhibited migration of SMC to either 140K or the HBDA40K mixture by approximately 50%. Interestingly, heparin inhibited SMC migration to either 140K or the HBD/ 140K mixture equivalently, by about 2096, suggesting that heparin may be interacting with a site on 140K. This possibility was confirmed by assessing SMC migration in the presence of both heparin and mAb C6.7; in the presence of both reagents, SMC migration to either 140K or the HBD/140K mixture decreased to nearly background levels, thereby suggesting that cooperative interactions between two sites on TSP may be involved. Furthermore, mAb A2.5 did not inhibit SMC migration to the HBD/140K mixture, reinforcing the likelihood that a heparin-binding site within 140K was involved. Thus, the priming effect of the HBD on SMC chemotaxis to 140K may involve conformational changes in the 140 kD domain driven by its interaction with the HBD.
SMC receptors involved in TSP-mediated chemotaxis Several distinct cell surface molecules, including a,ps integrins and GPIV (CD36), have been shown to serve as TSP receptors on a variety of cell types (Lawler et al., 1988; Asch et al., 1987) . We, therefore, tested antibodies to these molecules to determine whether these receptors mediated the migration of SMC to TSP. MAb LM142, specific for the a, subunit of the a,p3 vitronectin receptor (Cheresh and Spiro, 1987) , partially inhibited SMC migration (Fig. 4) . At 200 pgiml mAb LM142 inhibited migration by about 60% (P < 0.05). Interestingly, the same concentration of mAb LM609, specific for the avp3 complex (Cheresh and Spiro, 1987) , did not significantly inhibit migration. In contrast, SMC chemotaxis to 1 pM vitronectin (15.8 2 1.0 SMC/field) was reduced by 70% (4.7 ? 0.6 SMC/field) in the presence of 200 pg/ml mAb LM609. These data suggested that the a, subunit was mediating SMC migration through its association with an alternative p subunit. However, antibodies to the and p3 subunits did not significantly inhibit migration. Additionally, the synthetic peptides GRGDS and GRGES failed to significantly inhibit SMC migration, indicating that the RGD amino acid sequence in TSP was not involved in SMC migration to TSP. Similarly, three different mAbs directed against GPIV had no effect on SMC migration. These results revealed that the 01, integrin subunit associated with a f3 subunit other than PI or PB is important in the migratory response of SMC to TSP. Furthermore, the lack of complete inhibition by 01, specific antibodies suggested that another SMC receptor may also be involved in mediating SMC migration to TSP. TSP potentiates PDGF-mediated SMC chemotaxis TSP mRNA levels increase within 30 minutes of PDGF stimulation of SMC and, subsequently, TSP expression increases within 2 hours (Majack et al., 1985 (Majack et al., , 1987 . Therefore, within this short time frame after were placed in the upper wells of modified Boyden chambers. PDGF (10 ngiml), bFGF (10 ngiml), TSP (50 nM), or a mixture of TSP and either PDGF or bFGF was placed into the lower wells and SMC migration allowed to proceed for 6 hours a t 37°C. The number of migrating SMC was scored as described in Materials and Methods with triplicate filters prepared for each treatment. Five high power (x400) fields were scored for each filter and values shown represent the mean i-S.E.M. '2P <: 0.025, migration of SMC in response to a mixture of PDGF and 50 nM TSP was compared to SMC migration in response to the calculated additive effect of each attractant individually.
PDGF stimulation, the extracellular environment contains both PDGF and TSP; each of which can stimulate SMC migration. It was therefore of interest to determine whether PDGF and TSP together would affect SMC migration differently than either molecule alone. In the presence of suboptimal concentrations of TSP, SMC motility to PDGF was increased significantly, P < 0.025, above the calculated additive response of SMC to each attractant individually (Fig. 5 ) . This effect was specific for PDGF, since the addition of suboptimal concentrations of TSP to bFGF did not elicit similar potentiation. The enhancing effect of' TSP on PDGFmediated migration was consistent among different batches of TSP and PDGF. Furthermore, the potentiation of SMC motility was dependent on TSP concentration (Fig. 6) , with the extent of potentiation increasing as the concentration of TSP increased. In the presence of 50 nM TSP SMC migration was about 50% higher than the calculated additive response of SMC to each attractant. Peak enhancement of PDGF-mediated migration was seen at 100 nM TSP, approximately a 60% increase, with higher concentrations of TSP inducing less of a response. Overall, SMC migration to the combination of PDGF and TSP was greater than migration to either 10 ng/ml PDGF or 1 pM TSP, concentrations that yielded maximal migration. As with SMC migration to TSP alone, anti-TSP mAbs were used to determine which domain of TSP mediated the enhancement of PDGF-mediated SMC migration (Fig. 7a) . In the presence of 75 pg/ml mAb C6.7 motility decreased by about 80%; at 200 pg/ml mAb C6.7 the response was completely abolished. The ability of mAb C6.7 to completely inhibit migration to the combination of 50 nM TSP and PDGF was surprising, considering that PDGF is typically a strong stimulus for SMC migration, and suggested that specific interactions between the two molecules might be responsible. Otherwise, an antibody against TSP would not be capable of knocking out the response to PDGF as well. None of the other TSP-specific mAbs were inhibitory.
Since the 140 kD fragment of TSP partially supported SMC migration, we evaluated its effectiveness at suboptimal concentrations in potentiating migration to PDGF (Fig. 7b) . Neither 140K nor the HBD potentiated SMC migration above the calculated additive response. Based on the evidence that the HBD enhanced SMC migration to 140K, we also looked at whether a combination of the HBD and 140K would potentiate SMC migration to PDGF. This was not the case; indeed the migratory responses to the combination of PDGF, 140K, and the HBD were similar to the responses observed with PDGF and either fragment alone. Thus, it appeared that potentiation of SMC migration to PDGF mediated by suboptimal concentrations of TSP could only be elicited by intact TSP.
Complete inhibition by mAb C6.7 of SMC chemotaxis to the combination of 50 nM TSP and PDGF suggested that PDGF indirectly stimulated SMC motility, perhaps by inducing TSP synthesis. Thus, TSP could function as an autocrine motility factor for SMC. In order to establish whether this mechanism was feasible, we assessed PDGF-mediated motility in the presence of either mAb C6.7 or cycloheximide. SMC preincubated with mAb C6.7 were unable to migrate in response to PDGF (Fig. 8a) . Inhibition was dose dependent with migration reduced to background levels in the presence of 200 pgiml mAb C6.7. Alternately, SMC were preincubated with 10 pg/ml cycloheximide to inhibit the induction of TSP synthesis following exposure to PDGF. Cycloheximide-treated SMC were assayed for migration to either TSP or PDGF (Fig. 8b ). Chemotaxis to PDGF was dramatically inhibited, P < 0.01, in the presence of cycloheximide. Furthermore, chemotaxis in response to TSP was also reduced in cycloheximidetreated SMC, P < 0.05, but to a much lesser extent.
These experiments indicated that cell surface-associated TSP is essential for SMC chemotaxis to PDGF, and that PDGF stimulates SMC motility indirectly, through induction of TSP expression which serves as an autocrine motility factor.
DISCUSSION
A critical event in the early stages of atherosclerotic lesion development is the migration of SMC from the media into the intima of the blood vessel wall. In the present study, we investigated the role of TSP in SMC migration and found that TSP was a potent mediator of SMC migration. In comparison with concentrations of bFGF or PDGF-BB which resulted in maximal levels of migration, TSP elicited a 40% greater migratory response. Of particular interest was the finding that suboptimal concentrations of TSP potentiated SMC migration to PDGF. SMC migration to the combination of TSP and PDGF was greater than the maximal response observed to PDGF alone, suggesting that interactions of growth factors with ECM molecules may accelerate responses initiated by one or the other. Further investigation demonstrated that TSP is a n autocrine motility factor for vascular SMC and is essential for PDGFmediated motility. The availability of TSP at sites of vascular damage and inflammation, both kinetically and spatially, correlates with early events after injury (Raugi et al., 1990; Botney et al., 1992) and suggests that TSP may be an important modulator of these processes. Furthermore, since PDGF expression is also an early response to vascular injury (Walker et al., 19861 , these results emphasize the complex interactions that can be expected to influence SMC behavior following vascular damage.
The interaction of TSP with SMC has been previously studied with respect to proliferation (Majack et al., 1986 (Majack et al., , 1988 . TSP was demonstrated to be essential for SMC proliferation in response to PDGF, an effect presumably involving the HBD since heparin was inhibi- partially inhibited SMC migration to 140K. However, heparin in conjunction with mAb C6.7 inhibited migration to 140K almost completely. These results suggest that a conformationally sensitive site on the 140 kD fragment, possibly the secondary heparin-binding site lying within the type I repeats of TSP (Guo et al., 1992a,b) , binds heparin and plays a role in SMC migration. Exposure of a cryptic heparin-binding site within the 140K fragment upon proteolytic cleavage has been previously observed, and may have physiological implications since cellular responses to intact vs. proteolyzed matrix proteins are often distinct (Guo et al., 1992a; Chelberg et al., 1989) . Although the evidence argues against a role for the HBD interacting with heparan sulfate proteoglycans in mediating SMC migration, the data suggest that cell surface proteoglycans may interact with the heparin-binding site in 140K. Interestingly, heparin inhibits TSP-mediated potentiation of SMC proliferation to EGF and shifts TSP localization from the SMC cell surface into the media (Majack et al., 1986 (Majack et al., , 1988 . Such modulation of TSP expression patterns, rather than inhibiting SMC motility, could accelerate SMC migration by raising concentrations of soluble TSP in areas surrounding injured endothelium. Thus, TSP could differentially affect SMC responses depending on changes in TSP-SMC association and TSP functional domains involved.
Adhesion of SMC to TSP is mediated through the a,& vitronectin receptor (Lawler et al., 1988) . We have demonstrated a role for an a,-containing integrin, but not a,p3, in SMC migration to TSP. Lack of inhibition of SMC migration with either or p3 antibodies suggested that the SMC receptor mediating migration is neither the a,P3 receptor involved in SMC adhesion (Lawler et al., 1988) nor the a,pl receptor involved in adhesion of epithelial cells to vitronectin (Bodary and McLean, 1990) . Neurite outgrowth of embryonic chick retinal neurons on TSP was inhibited by antibodies to a, (Neugebauer et al., 19911 , implicating a,-containing integrins in this specialized form of migration. Overall these data indicate the presence of multiple functional receptors on SMC surfaces that interact with TSP, including heparan sulfate proteoglycans in TSP-dependent SMC proliferation and a, integrins in TSP-mediated SMC motility.
Although the effects of PDGF on SMC migration have been extensively studied, little is known about the interaction of growth factors with accessory molecules important in cell migration, such as components of the ECM. Expression of TSP and PDGF a t sites of vascular injury is linked both functionally and temporally. PDGF treatment of SMC stimulates a rapid, though transient, rise in TSP expression (Majack et al., 19851 , and TSP can also be derived from activation of platelets, monocytes, fibroblasts, and endothelial cells (Mosher, 1990) . Sources of PDGF include activated platelets, monocytes, endothelial cells, and SMC themselves (Ross, 1986) . Both TSP and PDGF are expressed by similar cell types, and with similar kinetics after cell activation, thus leading to their colocalization a t sites of vascular damage. Based on this evidence, we investigated the effect of suboptimal concentrations of TSP on PDGF-mediated SMC migration. Our data support a inhibited SMC chemotaxis to PDGF. SMC were preincubated with either mAb C6.7 (30 minutes, concentration as indicated) or cycloheximide (16 hours, 10 pgiml) before being placed into the upper wells of the chemotaxis chamber. In addition, mAb C6.7 or cycloheximide was present throughout the assay. TSP (1 pM) or PDGF (0.3 nM), as indicated, was placed into the lower wells and the chamber was incubated for 6 hours at 37°C. The number of migrating SMC was scored in triplicate as described in Materials and Methods. Five high power (~4 0 0 ) fields were scored for each filter and values represent the mean % control % S.E.M. role for TSP in the potentiation of PDGF-mediated migration. The effect was dose dependent, specific for TSP, and mediated by a site in the 140 kD domain. Maximal potentiation was observed between 50 and 100 nM TSP, a log-fold lower than the concentrations necessary for maximal stimulation of SMC migration by TSP alone. Additionally, 50 nM TSP has been shown to stimulate S6 kinase and phosphatidylinositol turnover in SMC (Scott-Burden et al., 19881 , indicating that TSP elicits physiologically relevant responses within this concentration range.
SMC migration to the combination of TSP and PDGF was completely inhibited by mAb C6.7, an unlikely result if TSP and PDGF were acting independently. Alternate scenarios include a functional linkage between TSP and PDGF receptors on the SMC surface or a specific bimolecular complex formed by TSP and PDGF. Raines et al. (1992) demonstrated binding of PDGF to the ECM protein SPARC which inhibited PDGF binding to its receptor, but failed to detect PDGF binding to TSP under similar conditions. We investigated the possible interaction of TSP with PDGF by determining if radiolabeled TSP coimmunoprecipitated with PDGF, and found no evidence for a specific interaction (data not shown). Therefore, we took two alternate approaches in elucidating a mechanism for potentiation of SMC chemotaxis in the presence of both PDGF and TSP. Since anti-TSP mAbs have been shown to disrupt the association of TSP with the SMC surface (Majack et al., 19881 , we preincubated SMC with mAb C6.7 before assessing migration to PDGF. In the presence of mAb C6.7, SMC were unable to migrate to PDGF, indicating that cell surface-associated TSP is critical in this process. Additionally, it was evident that PDGF would induce de novo TSP synthesis during the 6 hour assay period (Majack et al., 1987) . By using cycloheximide to inhibit de novo protein synthesis, we investigated the importance of TSP in SMC motility to PDGF. Our results demonstrated that TSP is an essential autocrine motility factor for SMC; i.e., PDGF stimulates motility indirectly through the induction of TSP synthesis. Thus, inhibition of either TSP synthesis or TSP-SMC interactions resulted in a diminished SMC migratory response. Although the combination of PDGF-AA and bFGF has been demonstrated to potentiate SMC proliferation (Majack et al., 1990) , the mechanism of action involved remains unclear. Similarly, the pathway(s) through which TSP facilitates EGF-dependent SMC proliferation (Majack et al., 1986) has not been identified. Overall, the potentiation of growth factor-mediated functional responses by TSP, such as SMC migration and proliferation, reinforces the autocrine nature of TSPs interactions with SMC.
Recently, a more comprehensive picture of the role of TSP in SMC behavior has begun to emerge. No longer defined only as a component of the ECM, TSP has been shown to exert pleiotropic effects on SMC. First, TSP is a n immediate-early response gene activated following PDGF treatment of SMC (Majack et al., 1987) . Second, TSP promotes adhesion of SMC (Lawler et al., 1988) . Third, TSP functions as a n autocrine growth factor, potentiating EGF-and PDGF-mediated SMC proliferation (Majack et al., 1986 (Majack et al., , 1988 . Fourth, we have demonstrated that TSP is a potent modulator of SMC migration and is essential in SMC migration to PDGF. In vivo, TSP has been localized to atherosclerotic plaques, regions of SMC migration and proliferation (Botney et al., 1992; Wight et al., 1985) . Furthermore, evidence that endothelial cell adhesion and proliferation are inhibited by TSP (Lahav, 1988; Bagavandoss and Wilks, 1990) suggests that TSP may play a dual role in atherosclerosis; promoting SMC adhesion, migration, and proliferation in the vascular intima while preventing endothelial cells from doing the same. Thus, TSP influences several aspects of SMC physiology important in the early events preceding the development of an atherosclerotic lesion. By understanding the molecular switches controlling these pathways in greater detail, the molecular targets most amenable to early and effective therapeutic intervention can be identified.
